menu search

Adverum biotechnologies to participate in rbc capital markets global healthcare conference

REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish ...

May 10, 2023, 4:05 pm

Surgalign to collaborate with dr. alexander vaccaro and dr. pierce nunley to advance holo™ ai insights and its artificial intelligence technologies

DEERFIELD, Ill., May 03, 2023 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating t...

May 3, 2023, 12:30 pm

Accelus sells remi robotic navigation system to alphatec and announces leadership change to drive growth and innovation

PALM BEACH GARDENS, Fla., April 19, 2023 (GLOBE NEWSWIRE) — Accelus, a privately held medical technology company focused on accelerating the adoptio...

April 19, 2023, 8:07 pm

Ascendis pharma: is dip on transcon application a buy opportunity?

Ascendis has enjoyed a market cap valuation of >$6bn thanks to its TransCon technology platform and single approved asset SKYTROFA. SKYTROFA is approv...

April 6, 2023, 3:11 pm

Dexcom (dxcm) launches g6 glucose monitoring system in canada

Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - f...

March 24, 2023, 1:45 pm

Gilead (gild) announces os data on yescarta from zuma-7 study

Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical ...

March 22, 2023, 4:01 pm

Surgalign schedules fourth quarter and full year 2022 earnings release for march 30, 2023

DEERFIELD, Ill., March 21, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating ...

March 21, 2023, 8:30 am

2seventy bio: karmma-3 finally releases positive results

2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Re...

March 9, 2023, 8:45 am

Surgalign to participate at the 2023 aaos annual meeting orthodome in las vegas

Dr. Rick C. Sasso, renowned spinal surgeon to highlight Surgalign’s HOLO Portal™ Surgical Guidance System on the OrthoDome Panel on March 8, 2023 ...

March 3, 2023, 1:30 pm

Medical city frisco is the latest hospital to utilize surgalign’s holo portal surgical guidance system

This represents the first site in Texas; Medical City Frisco to leverage the benefits of HOLO Portal, the world’s first artificial intelligence (AI)...

March 2, 2023, 1:30 pm

Cidara to present at esmo targeted anticancer therapies congress

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics des...

February 28, 2023, 8:00 am

Ocular therapeutix: a 'buy' on maturing wet amd data

This weekend, OCUL released very encouraging data in wet AMD. I review this data herein, noting, in particular, the reduction in treatment burden asso...

February 12, 2023, 9:09 pm

Vericel announces fda approval of nexobrid for the treatment of severe thermal burns in adults

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or f...

December 29, 2022, 6:45 pm

Astrazeneca a ‘buy' for project pipeline potential – broker

Shore Capital has reiterated its ‘buy' stance on pharma giant AstraZeneca following data on its late-stage breast cancer drugs presented at a San An...

December 9, 2022, 11:32 am

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to ...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to ...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to ...

November 11, 2022, 5:00 pm

Candel therapeutics announces late-breaking oral presentation at sitc annual meeting with data on can-2409 in combination with nivolumab in a phase 1 mechanistic clinical trial in patients with high-g

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to ...

November 11, 2022, 5:00 pm

Gsk loses almost £1.7bn value after drug trial failure

Almost £1.7bn was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) in opening deals after the drug developer revealed a late-stage study failed to...

November 7, 2022, 3:31 am

Cidara therapeutics to present at the 24th annual h.c. wainwright global investment conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics de...

September 6, 2022, 8:00 am


Search within

Pages Search Results: